1. Home
  2. NLOP vs ANTX Comparison

NLOP vs ANTX Comparison

Compare NLOP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Net Lease Office Properties of Beneficial Interest

NLOP

Net Lease Office Properties of Beneficial Interest

N/A

Current Price

$10.90

Market Cap

164.9M

Sector

N/A

ML Signal

N/A

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

N/A

Current Price

$5.36

Market Cap

172.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NLOP
ANTX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.9M
172.9M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
NLOP
ANTX
Price
$10.90
$5.36
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
98.5K
193.0K
Earning Date
05-19-2026
05-13-2026
Dividend Yield
52.20%
N/A
EPS Growth
N/A
32.56
EPS
1.27
N/A
Revenue
$118,915,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.81
$1.00
52 Week High
$30.26
$7.19

Technical Indicators

Market Signals
Indicator
NLOP
ANTX
Relative Strength Index (RSI) 35.49 43.06
Support Level N/A $3.91
Resistance Level $11.65 $5.51
Average True Range (ATR) 0.26 0.35
MACD -0.04 -0.07
Stochastic Oscillator 17.53 16.00

Price Performance

Historical Comparison
NLOP
ANTX

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns, operates, and finances a diversified portfolio of office properties mainly leased to corporate tenants on a single-tenant, net-lease basis. The company operates as a single operating and reportable segment focused on owning and managing office properties that generate revenue mainly from long-term lease agreements with tenants.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: